Abstract A088: Dual-agonist loaded "super adjuvant” nanoparticles as a modular platform for cancer vaccination

Abstract We report on the utility of a “super adjuvant” nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness the effective adjuvanticity of whole-pathogen vaccines combined with the safety profile of subunit vaccines. This lipid-based platform uniquely co-encapsulates agonists of the Stimulator of Interferon Genes (STING) and Toll-like Receptor 4 (TLR4) pathways to promote synergistic production of Type I interferons and other proinflammatory cytokines in antigen-presenting dendritic cells (DCs) and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs promoted increased antigen processing and presentation, drained efficiently to nearby lymph nodes, increased polyfunctional T and B cells, and improved tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells. Citation Format: Griffin I Kane, Tiana E Naylor, Christina F Lusi, Meghan L Brassil, Kim Wigglesworth, Haruka Mori, Prabhani U Atukorale. Dual-agonist loaded "super adjuvant” nanoparticles as a modular platform for cancer vaccination [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A088.